Stevanato Group (NYSE:STVN) Director Elisabetta Magistretti Sells 2,045 Shares of Stock

Stevanato Group S.p.A. (NYSE:STVN) Director Elisabetta Magistretti sold 2,045 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of €20.09, for a total transaction of €41,084.05. Following the completion of the transaction, the director directly owned 2,930 shares in the company, valued at €58,863.70. The trade was a 41.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stevanato Group Trading Up 1.9%

Shares of STVN traded up €0.38 during trading on Monday, reaching €20.65. 501,629 shares of the company traded hands, compared to its average volume of 541,629. The stock has a 50-day simple moving average of €18.80 and a 200-day simple moving average of €16.97. The stock has a market cap of $6.25 billion, a PE ratio of 36.87, a price-to-earnings-growth ratio of 1.70 and a beta of 0.77. Stevanato Group S.p.A. has a twelve month low of €12.89 and a twelve month high of €28.00. The company has a quick ratio of 1.08, a current ratio of 1.61 and a debt-to-equity ratio of 0.21.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings data on Friday, May 8th. The company reported €0.11 earnings per share for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%.The company had revenue of €273.57 million for the quarter. During the same period in the prior year, the firm earned $0.10 earnings per share. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. On average, analysts anticipate that Stevanato Group S.p.A. will post 0.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. TD Cowen upgraded Stevanato Group to a “strong-buy” rating in a report on Wednesday, June 17th. Weiss Ratings raised Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 16th. Finally, Wolfe Research initiated coverage on shares of Stevanato Group in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $21.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy”.

Institutional Trading of Stevanato Group

Large investors have recently made changes to their positions in the company. GW&K Investment Management LLC lifted its stake in Stevanato Group by 76.2% in the fourth quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock worth $49,000 after acquiring an additional 1,055 shares during the last quarter. Fifth Third Bancorp increased its position in shares of Stevanato Group by 22.6% in the 1st quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock valued at $58,000 after purchasing an additional 773 shares during the last quarter. State of Wyoming raised its holdings in shares of Stevanato Group by 39,216.7% in the 2nd quarter. State of Wyoming now owns 2,359 shares of the company’s stock valued at $58,000 after purchasing an additional 2,353 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Stevanato Group in the 3rd quarter valued at $68,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Stevanato Group by 1,268.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock worth $112,000 after purchasing an additional 4,250 shares during the last quarter.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.